Objective To evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis. Methods We conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software. Results A total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR = 0.28, 95%CI 0.16 to 0.50, I2 = 67%, P < 0.0001) compared to the control groups. In the subgroup analysis by cancer type, Mepitel reduced the incidence of radiation dermatitis in nasopharyngeal carcinoma (OR = 0.25, 95%CI 0.13 to 0.46, I2 = 0%, P < 0.0001), breast cancer (OR = 0.42, 95%CI 0.26 to 0.68, I2 = 24%, P = 0.0004), and various malignancies (OR = 0.10, 95%CI 0.06 to 0.16, I2 = 0%, P < 0.00001). Mepitel use was also associated with a lower incidence of moderate and severe skin injury in radiotherapy patients (RTOG grade II OR = 0.26, 95%CI 0.16 to 0.42, P < 0.00001; RTOG grade III OR = 0.19, 95%CI 0.12 to 0.30, P < 0.00001; RTOG grade IV OR = 0.10, 95%CI 0.03 to 0.36, P = 0.0005), as well as a reduction in the severity of radiation-induced skin damage (combined RISRAS score, MD= -0.74 95% CI -1.02 to -0.46, I2 = 95%, P < 0.00001; researcher RISRAS score MD= -0.47 95% CI -0.67 to -0.27, I2 = 90%, P < 0.00001; and patient RISRAS score MD= -1.19 95% CI -1.33 to -1.05, I2 = 39%, P < 0.00001). Additionally, patients treated with Mepitel experienced fewer cases of moist desquamation (OR = 0.46, 95%CI 0.25 to 0.83, I2 = 58%, P = 0.010), and shorter healing times (MD= -4.73, 95%CI -7.16 to -2.30, I2 = 98%, P = 0.0001). Conclusion Mepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.

Efficacy and safety of Mepitel film for radiodermatitis: a systematic review and meta-analysis

期刊论文
出版模式：

开放获取
发表日期：

2025年12月19日

查看全文

Xue Ren,
Hengjiao Wang,
Jing Liu,
YongXin Yuan,
Tong Wu,
Haibo Zhang,
Defu Yang,
Ying Yan,
Ying Xu,
Feng Wei

摘要

Objective

To evaluate the effects of Mepitel film on the prevention and treatment of radiodermatitis.

Methods

We conducted a systematic search across multiple databases, including PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, and SinoMed Database, from their inception until August 6, 2024. We identified randomized controlled trials (RCTs) or controlled clinical trials that assessed the effects of Mepitel film on radiodermatitis. The risk of bias was evaluated using the Revised Cochrane Risk-of-Bias tool for randomized trials (RoB2). Traditional meta-analysis was performed using RevMan 5.3 and Stata 14.0 software.

Results

A total of 27 studies involving 2,313 cancer patients were included. The pooled analysis indicated that Mepitel significantly reduced the incidence of radiation dermatitis (OR = 0.28, 95%CI 0.16 to 0.50, I² = 67%, P < 0.0001) compared to the control groups. In the subgroup analysis by cancer type, Mepitel reduced the incidence of radiation dermatitis in nasopharyngeal carcinoma (OR = 0.25, 95%CI 0.13 to 0.46, I² = 0%, P < 0.0001), breast cancer (OR = 0.42, 95%CI 0.26 to 0.68, I² = 24%, P = 0.0004), and various malignancies (OR = 0.10, 95%CI 0.06 to 0.16, I² = 0%, P < 0.00001). Mepitel use was also associated with a lower incidence of moderate and severe skin injury in radiotherapy patients (RTOG grade II OR = 0.26, 95%CI 0.16 to 0.42, P < 0.00001; RTOG grade III OR = 0.19, 95%CI 0.12 to 0.30, P < 0.00001; RTOG grade IV OR = 0.10, 95%CI 0.03 to 0.36, P = 0.0005), as well as a reduction in the severity of radiation-induced skin damage (combined RISRAS score, MD= -0.74 95% CI -1.02 to -0.46, I² = 95%, P < 0.00001; researcher RISRAS score MD= -0.47 95% CI -0.67 to -0.27, I² = 90%, P < 0.00001; and patient RISRAS score MD= -1.19 95% CI -1.33 to -1.05, I² = 39%, P < 0.00001). Additionally, patients treated with Mepitel experienced fewer cases of moist desquamation (OR = 0.46, 95%CI 0.25 to 0.83, I² = 58%, P = 0.010), and shorter healing times (MD= -4.73, 95%CI -7.16 to -2.30, I² = 98%, P = 0.0001).

Conclusion

Mepitel interventions significantly reduced RTOG grades and RISRAS scores, decreased the risk of moist desquamation, and shortened healing times for radiation-induced dermatitis in cancer patients. Further clinical studies are needed to better understand the relationship between Mepitel and radiation dermatitis in this patient population.